Fennec Pharmaceuticals
FENC
28 hedge funds and large institutions have $63.2M invested in Fennec Pharmaceuticals in 2022 Q2 according to their latest regulatory filings, with 1 funds opening new positions, 3 increasing their positions, 10 reducing their positions, and 1 closing their positions.
1% more call options, than puts
Call options by funds: $727K | Put options by funds: $723K
0% more funds holding
Funds holding: 28 → 28 (0)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
0% more first-time investments, than exits
New positions opened: 1 | Existing positions closed: 1
0.65% less ownership
Funds ownership: 43.98% → 43.32% (-0.65%)
1% less capital invested
Capital invested by funds: $64.1M → $63.2M (-$877K)
70% less repeat investments, than reductions
Existing positions increased: 3 | Existing positions reduced: 10
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SCM
Solas Capital Management
Darien,
Connecticut
|
+$161K |
| 2 |
TRCT
Tower Research Capital (TRC)
New York
|
+$22.3K |
| 3 |
Simplex Trading
Chicago,
Illinois
|
+$12.6K |
| 4 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
+$940 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$493K |
| 2 |
6CM
683 Capital Management
New York
|
-$342K |
| 3 |
Millennium Management
New York
|
-$88.7K |
| 4 |
Morgan Stanley
New York
|
-$57.1K |
| 5 |
JP Morgan Chase
New York
|
-$50.1K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
26
BNP Paribas Financial Markets
Paris,
France
| $949 | -$19.1K | -3,286 | -95% |
|
|
FAG
27
Fortitude Advisory Group
Gig Harbor,
Washington
| – | -$8K | -1,500 | Closed |
|
28
UBS Group
Zurich,
Switzerland
| – | -$5.99K | -1,032 | -94% |
|
29
Toronto Dominion Bank
Toronto, Ontario,
Ontario, Canada
| – | -$58 | -10 | -14% |
|
FENC Hedge Fund Activity: Q2 2022 in Review
28 of the 5,936 institutional investors tracked by Wall St. Rank reported a position in Fennec Pharmaceuticals (FENC) for Q2 2022, worth a combined $63.2M — down 1.4% from $64.1M a quarter earlier.
Fund positioning in FENC was balanced in Q2 2022: 1 fund opened new positions, 1 closed out, 3 added to existing stakes and 10 trimmed.
The largest buyer was Solas Capital Management, adding an estimated $161K. The largest seller was Susquehanna International Group, cutting an estimated $493K.
- 28 institutional investors held Fennec Pharmaceuticals (FENC) as of Q2 2022, unchanged from Q1 2022.
- Funds reported $63.2M of Fennec Pharmaceuticals stock for Q2 2022, down 1.4% quarter-over-quarter.
- 1 fund opened new Fennec Pharmaceuticals positions in Q2 2022 and 1 closed out, a net change of 0 holders.
- The largest Fennec Pharmaceuticals buyer in Q2 2022 was Solas Capital Management, an estimated $161K added.
- The largest Fennec Pharmaceuticals seller in Q2 2022 was Susquehanna International Group, an estimated $493K sold.
Based on aggregated 13F filings for Q2 2022.